Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real Life Second-Line Nivolumab in Advanced Non-Small Cell Lung Cancer: a French Observational Multicenter Study of 259 Patients (ABCT-IMMUNOBZH)

NCT04858204 is registered in ClinicalTrials.gov with University Hospital, Brest as lead sponsor.

NCT NCT04858204
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04858204 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real Life Second-Line Nivolumab in Advanced Non-Small Cell Lung Cancer: a French Observational Multicenter Study of 259 Patients (ABCT-IMMUNOBZH)
Lead sponsor
University Hospital, Brest
Phase
Observational
Overall status
Completed
Start date
April 14, 2017
Completion date
November 1, 2017
Enrollment
259 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc